[alpha 1-proteinase inhibitor in breast cancer].
Level of alpha 1-proteinase inhibitor (alpha 1-Pi) and antitryptic activity in blood serum were assessed in 167 patients with breast cancer and 30 cases of benign lesions. An increase in blood serum-alpha 1-Pi level was shown to be associated with tumor advancement but could not be regarded as a marker of cancer. Concentration of the inhibitor exceeded 8 mg/ml in 83.4% of cases with metastatic breast cancer but was as a rule, equal to or below that value in metastasis--free patients. Those two groups were prognostically different. Morphological analysis established a correlation between blood serum-alpha 1-Pi level, on the one hand, and grade of malignancy, degree of pathologic changes in tumor stroma and extent of lymph node involvement, on the other.
Demidov
V P
VP
Iakubovskaia
R I
RI
Karmakova
T A
TA
Avdeev
G I
GI
Komissarov
A B
AB
Sorokin
E E
EE
Kotova
T S
TS
D001941:Breast Diseases / Q000175:diagnosis; D001943:Breast Neoplasms / Q000097:blood* / Q000175:diagnosis; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D005779:Immunodiffusion; D008207:Lymphatic Metastasis / Q000175:diagnosis; D000515:alpha 1-Antitrypsin / Q000032:analysis*
D000515:alpha 1-Antitrypsin
alfa1-Ingibitor proteinaz pri rake molochnoĭ zhelezy.